Global Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Type (Adenocarcinoma, Squamous Cell Carcinoma), By Treatment (Chemotherapy, Targeted Therapy), By End-Use Industry (Hospitals, Homecare), By Region - Industry Forecast 2026-2033

Report ID: SQMIG25K2005 | Region: Global | Published Date: December, 2024
Pages: 165 |Tables: 36 |Figures: 74

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Non-Small Cell Lung Cancer Market size was valued at USD 30.68 Billion in 2024 and is poised to grow from USD 34.95 Billion in 2025 to USD 99 Billion by 2033, growing at a CAGR of 13.9% during the forecast period (2026–2033).

    Top Players in the Global Non-Small Cell Lung Cancer Market  'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'AstraZeneca (United Kingdom) ', 'Bristol-Myers Squibb Company (United States) ', 'Merck & Co., Inc. (United States) ', 'Novartis AG (Switzerland) ', 'Pfizer Inc. (United States) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Bayer AG (Germany) ', 'Eli Lilly and Company (United States) ', 'GlaxoSmithKline plc (United Kingdom) ', 'Sanofi (France) ', 'AbbVie Inc. (United States) ', 'Johnson & Johnson (United States) ', 'Gilead Sciences, Inc. (United States) ', 'Amgen Inc. (United States) ', 'Boehringer Ingelheim GmbH (Germany) ', 'Daiichi Sankyo Company, Limited (Japan) ', 'Astellas Pharma Inc. (Japan) ', 'Biogen Inc. (United States) ', 'Regeneron Pharmaceuticals, Inc. (United States)'

    Among the factors driving the growth of the NSCLC market are the rising rates of lung cancer caused by smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion.

    The expansion of the non-small cell lung cancer treatments market is also being aided by an increase in diagnoses of non-small cell lung cancer and an increase in awareness in both developed and developing regions. The inclusion of non-small cell cancer treatments in the pipelines of leading market participants, along with increased spending by major players in research and development activities, are also propelling the market expansion internationally.

    By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.

    Related Reports

    Lung Cancer Market
    Buy Now GET FREE SAMPLE
    Lung Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE
    Lung Cancer Surgery Market
    Buy Now GET FREE SAMPLE
    Oncology Market
    Buy Now GET FREE SAMPLE
    Cancer Immunotherapy Market
    Buy Now GET FREE SAMPLE
    Cancer Biological Therapy Market
    Buy Now GET FREE SAMPLE
    Cancer Cachexia Market
    Buy Now GET FREE SAMPLE
    Cancer Diagnostics Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Non-Small Cell Lung Cancer Market

    Report ID: SQMIG25K2005

    $5,300
    BUY NOW